Francis Collins
Showing 1–15 of 18 transcripts.
- Milken Institute1h 3m
"What Faith Means to Me" | Global Conference 2025
Richard Sandler, Sharon Brous, Francis Collins, Michael Dimock, T.D. Jakes
A panel of religious and scientific leaders discussed how the U.S. is experiencing a plateau in religious affiliation alongside a pervasive spiritual identity, noting that pandemic-induced isolation exacerbated health crises and social division. Experts including Dr. Francis Collins, Bishop T.D. Jakes, and Rabbi Sharon Brous debated strategies to bridge the gap between faith and science while advocating for a shift from digital algorithms to authentic, in-person community building. The group concluded that overcoming societal polarization requires active listening, a rejection of misinformation, and a deliberate return to local connections to restore social cohesion.
- Milken Institute48 min
Toward a Flourishing Future | Global Conference 2025
Michael Milken, Sian Beilock, Jon Clifton, Francis Collins, Jenny Johnson
A multi-disciplinary panel convened to redefine leadership through the lens of human flourishing, contrasting stagnant global GDP metrics with critical declines in mental well-being, youth purpose, and social connection. Experts from Dartmouth, Gallup, and financial sectors outlined a roadmap integrating physical health, ethical education, and blockchain-enabled financial democratization to counter rising anxiety and workplace misery. The discussion concluded with a call to embed these flourishing dimensions into public policy, advocate for mandatory civic service, and utilize technology to dismantle barriers to economic opportunity.
- Lex Fridman2h 22m
Jay Bhattacharya: The Case Against Lockdowns | Lex Fridman Podcast #254
Jay Bhattacharya, Lex Fridman, Francis Collins
Stanford Professor Jay Bhattacharya argues that pandemic policies should have prioritized "focus protection" for vulnerable populations over broad lockdowns, asserting that the infection fatality rate remains low and that lockdowns inflicted catastrophic harm through economic disruption and mental health crises. He details how the Great Barrington Declaration was met with hostility from health officials like Francis Collins and Anthony Fauci, who dismissed the strategy despite evidence of massive case under-reporting and incidental deaths misattributed to the virus. Bhattacharya concludes that the virus will become endemic with mild reinfections, urging public health leaders to abandon fear-based tactics and foster open scientific debate to rebuild trust.
- Lex Fridman1h 27m
Francis Collins: National Institutes of Health (NIH) | Lex Fridman Podcast #238
Outgoing NIH Director Francis Collins addresses the likely natural origin of COVID-19, refutes direct lab-leak assertions, and defends the scientific consensus on treatments like ivermectin while distinguishing between general gain-of-function research and dangerous enhanced pathogens. As he prepares to conclude his unprecedented tenure overseeing three presidential administrations, Collins highlights major breakthroughs in brain mapping and gene editing while warning that the erosion of public trust in objective data poses a greater long-term threat than the virus itself. He concludes by arguing for humility in scientific communication and expressing his belief that the convergence of rigorous research and ethical altruism is essential for improving human health.
- Milken Institute1h 2m
Lessons Learned from COVID-19: Are There Silver Linings for Biomedical Innovation?
Esther Krofah, Francis Collins, Richard Moscicki, Ellen Sigal, Janet Woodcock
Hosted by Faster Cures, a webinar convened NIH officials and industry leaders to analyze the COVID-19 pandemic's acceleration of biomedical innovation, highlighting achievements such as the ACTIV partnership's master protocols and the RADx initiative's diagnostic scaling. The discussion detailed how the crisis forced a shift toward competitive collaboration, decentralized trials, and the successful achievement of diverse vaccine trial enrollment, while simultaneously exposing critical infrastructure gaps in clinical trial execution and real-world data integration. Panelists concluded with a consensus that emergency-driven reforms must be institutionalized through permanent policy changes and public-private partnerships to sustain preparedness for future health threats.
- Milken Institute1h 22m
Toward a Healthier Future
Will Durant, Mike Milken, Tanisha Carino, Michael Milken, Francis Collins, Susan Desmond-Hellmann, Bernard J. Tyson, Seema Verma, Sue Desmond-Hellman
Representatives from the Gates Foundation, Kaiser Permanente, CMS, and NIH converged to outline a unified strategy shifting global health systems from reactive treatment toward proactive prevention and precision medicine. Leaders highlighted specific breakthroughs in gene therapy, AI-driven neural decoding, and data interoperability while proposing structural reforms to align financial incentives with long-term population wellness and disease eradication. The consensus among these major institutions emphasizes that future economic prosperity and reduced healthcare costs depend on integrating community infrastructure, digital infrastructure, and innovative financing models to address challenges ranging from mental health crises to rare genetic disorders.
- Milken Institute29 min
A Conversation with Francis Collins, Director, National Institutes of Health
Francis Collins, Meg Tirrell, Richard Ditizio, Synim Rivers
The event highlights a critical gender and racial leadership gap in healthcare, where women comprise half the workforce but hold only 3% of CEO roles, prompting organizations like Horizon Pharma to sign diversity pledges and adopt business resource groups to drive financial and clinical innovation. Parallel to these corporate initiatives, the NIH's "All of Us" research program and the Brain Initiative are launching large-scale, data-driven efforts to individualize medicine and accelerate cures for Alzheimer's and other neurological conditions by mapping billions of neurons and enrolling a diverse cohort of one million participants. These combined strategies aim to transform healthcare from a one-size-fits-all model into a precision-based system supported by robust funding, emerging gene therapies for sickle cell disease, and immunotherapy breakthroughs for metastatic cancers.
- Milken Institute1h 12m
The Future of Health 2018
Tanisha Carino, Francis Collins, Diana DeGette, Jim Yong Kim, Michael Milken, Rajiv Shah
At a recent biomedical and economic conference, leaders discussed the transformative $3 billion 21st Century Cures Act and the ambitious "All of Us" program, which aims to recruit one million participants to generate personalized genomic and health data while addressing the opioid crisis through standardized research. Complementing these health initiatives, the World Bank introduced a Human Capital Index to rank nations on health and education outcomes, urging G20 leaders and investors to fund early development and infrastructure to mitigate global risks like automation-driven inequality and obesity-related economic burdens. These strategies collectively emphasize that sustained economic growth and stability depend on treating human capital investment as a critical driver of national sovereignty and future market resilience.
- Milken Institute46 min
The Future of Health: A New World of Collaboration
Michael Milken, Francis Collins, Lynn Goldman, Bob Hugin
The National Institutes of Health, alongside corporate leaders like Celgene and academic institutions such as GW School of Public Health, is driving a decade-long strategic shift toward cross-sector collaboration to address mounting global health crises including opioid addiction, rising obesity-related cancers, and antimicrobial resistance. Key initiatives such as the Accelerating Medicines Partnership and the "All of Us" research program are deploying hundreds of millions in combined public and private funding to accelerate therapeutic discovery, leverage genomic data, and implement preventive structural interventions. This coordinated effort aims to reverse declining U.S. life expectancy trends and reduce the $4 trillion annual economic burden of chronic disease by aligning industry innovation cycles with public health objectives.
- Milken Institute58 min
Will You Live to a Healthy 100?
Francis Collins, Nir Barzilai, Elizabeth Blackburn, Pinchas Cohen, Joon Yun
A panel of researchers and investors shifts the longevity paradigm from extending chronological lifespan to maximizing healthspan by treating aging as a primary risk factor for chronic disease. Key figures such as Nir Barzilai, Elizabeth Blackburn, and Jun Jung highlighted actionable strategies including genetic insights from centenarians, the management of senescent cells, and the development of a $7 trillion market focused on restoring homeostatic capacity. These efforts are culminating in the imminent TAME clinical trial, which aims to establish aging as an FDA-recognized disease and unlock pharmaceutical investment for drugs like Metformin and Rapamycin to extend human health by two years.
- Milken Institute1h 12m
Accelerating Medical Research: The Bipartisan Quest for Cures
Margaret Anderson, Bob Hugin, Francis Collins, Mike Milken, Sara Radcliffe, Joe Barton
Hosted by Faster Cures, the 18th Global Conference convened over 160 sessions to address the critical intersection of biomedical innovation and economic stability, featuring strategic insights from Bob Hugin, Mike Milken, and Francis Collins regarding the shrinking purchasing power of NIH funding and China's aggressive bioscience investments. Speakers highlighted the urgent need to revise legislative frameworks, such as the bipartisan 21st Century Cures initiative and dynamic scoring practices, to counter a 23% decline in federal research support that threatens U.S. leadership against global competitors. The event concluded with a unified call to action for sustained advocacy and targeted funding for young scientists to secure future breakthroughs in precision medicine and drug repurposing.
- Milken Institute1h 3m
Chasing Cures: Reinventing the Business of Medicine
Melissa Stevens, John Noseworthy, Francis Collins, Mark Rothera, Melinda Richter, Monsef Slaoui
A panel of industry leaders and NIH officials advocates transforming biomedical research through open innovation models like the Accelerating Medicines Partnership, which pools $30 billion in funding to address major diseases by sharing data across pre-competitive collaborations. The discussion highlights a strategic shift toward patient-centric trials using real-world evidence and wearable technology to accelerate discovery while redefining value to include safety and patient-defined outcomes over mere cost containment. Looking ahead, experts anticipate breakthroughs in bio-electronic medicine and precision therapies, driven by regulatory reforms for orphan drugs and non-traditional partnerships that prioritize patient access over traditional discovery-to-commercialization silos.
- Milken Institute1h 11m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken, Mike Milken, Tom Frieden, Andy Van Eschenbach, Jack Andreyka
A comprehensive analysis of global bioscience reveals a dramatic increase in life expectancy and major breakthroughs in disease eradication, such as the near-elimination of polio and HIV management through programs like PEPFAR. Despite these successes, the sector faces a critical funding crisis where declining NIH grant success rates and inflation-adjusted budget cuts threaten the pipeline of young researchers and the translation of genetic discoveries into new treatments. Strategic initiatives like the Brain Initiative, precision medicine efforts, and the shift toward prevention are now essential to address rising chronic disease burdens and sustain the bioscience industry as a primary driver of US economic growth.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind (updated)
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
Prominent figures including Jack Andraka, Tejal Desai, and NIH Director Francis Collins present breakthroughs in nanotechnology, genomics, and cellular engineering that promise to revolutionize early cancer detection, drug delivery, and precision medicine. While these innovations leverage falling sequencing costs, portable diagnostic devices, and adaptive sensor platforms to bridge the gap between molecular discovery and clinical treatment, panelists express deep concern over a 20% decline in real research funding. The collective discourse underscores an urgent need to redirect resources toward young innovators and high-risk projects to sustain the momentum of this biological renaissance.
- Milken Institute58 min
The Role of Universities in Accelerating Bioscience Research
David Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
A consortium of leading academic figures, including Nobel Laureate David Baltimore and experts from Caltech, UCLA, and USC, convened to evaluate the intersection of biological engineering and clinical translation in the face of funding constraints. The panel detailed successful strategies for "engineered immunity" projects, such as converting muscle cells into antibody producers and conducting early-stage human trials within university settings, while highlighting the critical need for interdisciplinary programs that bridge the gap between engineering PhDs and MDs. Despite progress, participants identified a persistent "valley of death" in early-stage financing and urged a cultural shift toward professional management and team-based funding mechanisms to sustain innovation.